Study wrapper · #1205
Beyond GLP-1: Amylin-Based Pharmacotherapy and the Search for Better-Tolerated Weight-Loss Drugs.
Editor's note
A substantive mechanistic review of the amylin class at a moment when cagrilintide — as half of CagriSema — is nearing the market and several rivals are in mid-stage trials. The satiation-versus-aversion framing around calcitonin receptor engagement is the most useful contribution, offering a testable explanation for why tolerability differs across agents. As a narrative review it presents no new data, but it maps the competitive and pharmacological landscape our readers are already asking about. Good background for coverage of the amylin pipeline.
Plain-language abstract
Amylin is a hormone released alongside insulin that helps signal fullness, and drug makers are betting that amylin-mimicking peptides could match GLP-1 drugs on weight loss with less nausea. This review walks through the biology and the current crop of long-acting candidates, including cagrilintide, eloralintide, and petrelintide. A key idea is that how strongly a drug also hits the related calcitonin receptor may decide whether eating less feels like natural fullness or like feeling unwell. The authors frame tolerability, not just efficacy, as the race to watch in next-generation weight-loss drugs.